TRIAL IN PROGRESS: PHASE 1 DOSE-FINDING STUDY TO EVALUATE SAFETY AND TOLERABILITY OF CVGBM IN PATIENTS WITH NEWLY DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA

被引：0

作者：

Tabatabai, G. ^{[1
]}

von Baumgarten, L. ^{[2
]}

van den Bent, M. ^{[3
]}

Burger, M. C. ^{[4
,5
]}

Freres, P. ^{[6
]}

Glas, M. ^{[7
]}

Hau, P. ^{[8
]}

Herrlinger, U. ^{[9
]}

Mildenberger, I. ^{[10
]}

Neyns, B. ^{[11
]}

Schaefer, H. ^{[12
]}

Seidel, C. ^{[13
]}

de Vos, F. ^{[14
]}

Galot, R. ^{[15
]}

Whenham, N. ^{[15
]}

Wick, A. ^{[16
]}

Falk, M. ^{[17
]}

Chama, L. de Freitas ^{[18
]}

Henze, J. ^{[17
]}

Kelemen, P. ^{[17
]}

Koch, S. D. ^{[18
]}

Lutz, J. ^{[18
]}

Heidenreich, R. ^{[18
]}

Roche, P. Romer ^{[17
]}

Rost, T. ^{[17
]}

Schoenborn-Kellenberger, O. ^{[17
]}

Gnad-Vogt, U. ^{[17
]}

机构：

[1] Tubingen Univ Hosp, Tubingen, Germany

[2] Ludwig Maximilians Univ Munchen, Neurosurg Clin & Polyclin, Munich, Germany

[3] Erasmus MC Canc Inst, Rotterdam, Netherlands

[4] Goethe Univ Hosp, Frankfurt, Germany

[5] Hosp Frankfurt, Ctr Neurologsurg & Neurooncol, Frankfurt, Germany

[6] Liege Univ Hosp, Frankfurt, Germany

[7] Univ Med Essen, Essen, Germany

[8] Univ Hosp Regensburg, Regensburg, Germany

[9] Univ Bonn, Bonn, Germany

[10] Mannheim Univ, Med Ctr, Mannheim, Germany

[11] Univ Hosp Brussels, Brussels, Belgium

[12] Univ Freiburg, Freiburg, Germany

[13] Univ Hosp Leipzig, Frankfurt, Germany

[14] Univ Med Ctr Utrecht, Frankfurt, Germany

[15] Univ St Luc Hosp, Brussels, Belgium

[16] Heidelberg Univ Hosp, Heidelberg, Germany

[17] CureVac SE, Wiesbaden, Germany

[18] CureVac SE, Tubingen, Germany

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P06.09.B

引用

页码：47 / 47

页数：1

共 50 条

[11] Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed glioblastoma, MGMT-unmethylated
Chen, Zhong-ping
Guo, Chengcheng
Bacha, Jeffrey
Steino, Anne
Langlands, John
Kwan, Claire
Kanekal, Sarath
Schwartz, Richard
Lopez, Lorena
Brown, Dennis M.
CANCER RESEARCH, 2018, 78 (13)
[12] A phase 0/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients
Sanai, Nader
Desai, Siddhi
Margaryan, Tigran
Molloy, Jennifer
LoCascio, Costanza
Elliott, Mackenna
Harmon, Jocelyn
Hong, Amy
Melendez, Ernesto Luna
Wanebo, John
Braun, Kelly
Kennedy, William
Garcia, Michael
Yoo, Wonsuk
Tovmasyan, Artak
Tien, An-Chi
Mehta, Shwetal
CANCER RESEARCH, 2024, 84 (07)
[13] A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN NEWLY DIAGNOSED, MGMT-UNMETHYLATED AND RECURRENT GLIOBLASTOMA PATIENTS
Sanai, Nader
Umemura, Yoshie
Desai, Siddhi
Margaryan, Tigran
Molloy, Jennifer
Locascio, Costanza
Elliott, Mackenna
Harmon, Jocelyn
Hong, Amy
Melendez, Ernesto Luna
Wanebo, John
Braun, Kelly
Kennedy, William R.
Garcia, Michael
Yoo, Wonsuk
Tovmasyan, Artak
Tien, An-Chi
Mehta, Shwetal
NEURO-ONCOLOGY, 2024, 26
[14] A Combined Phase 0/1b Trial of ATM Inhibitor AZD1390 in Combination with Radiation in Patients with Newly Diagnosed, MGMT-Unmethylated Glioblastoma
Kennedy, W. R.
Sanai, N.
Desai, S.
Margaryan, T.
Molloy, J.
Lo Cascio, C.
Elliott, M.
Harmon, J.
Hong, A.
Melendez, E. Luna
Wanebo, J.
Braun, K.
Umemura, Y.
Kraus, R. D.
Barani, I. J., Jr.
Yoo, W.
Tovmasyan, A.
Tien, A. C.
Mehta, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E242 - E243
[15] Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM.
Chen, Zhong-ping
Guo, Cheng-cheng
Yang, Qun-ying
Li, Jia-wei
Wu, Shao-xiong
Langlands, John
Johnson, Gregory
Kwan, Claire
Kanekal, Sarath
Schwartz, Richard
Bacha, Jeffrey
Steino, Anne
Brown, Dennis
CANCER RESEARCH, 2021, 81 (13)
[16] Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study
Carpentier, Antoine F.
Verlut, Clotilde
Ghiringhelli, Francois
Bronnimann, Charlotte
Ursu, Renata
Fumet, Jean David
Gherga, Elisabeta
Lefort, Felix
Belin, Catherine
Vernerey, Dewi
Hervieu, Alice
Laheurte, Caroline
Meurisse, Aurelia
Jacquin, Marion
Malfroy, Marine
Fagnoni-Legat, Christine
Lehmann-Che, Jacqueline
Boullerot, Laura
Cuzzubbo, Stefania
Adotevi, Olivier
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[17] CLINICAL EFFICACY AND PK/PD RESPONSE IN A PHASE 0/2 STUDY OF NIRAPARIB PLUS RADIOTHERAPY FOR NEWLY-DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA
Sanai, Nader
Umemura, Yoshie
Margaryan, Tigran
Molloy, Jennifer
Zhang, Hualin
Knight, William
Harmon, Jocelyn
Hong, Amy
Wanebo, John
Braun, Kelly
Kennedy, William R.
Garcia, Michael
Barani, Igor
Yoo, Wonsuk
Tien, An-Chi
Tovmasyan, Artak
Mehta, Shwetal
NEURO-ONCOLOGY, 2024, 26
[18] Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) plus radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
Reardon, David A.
Kaley, Thomas Joseph
Dietrich, Jorg
Clarke, Jennifer Leigh
Dunn, Gavin
Lim, Michael
Cloughesy, Timothy Francis
Gan, Hui Kong
Park, Andrew J.
Schwarzenberger, Paul
Ricciardi, Toni
Macri, Mary J.
Ryan, Aileen
Venhaus, Ralph Rudolph
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[19] Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results
Wen, Patrick Y.
De Groot, John Frederick
Battiste, James
Goldlust, Samuel A.
Garner, James Stuart
Friend, John
Simpson, Jeremy Andrew
Damek, Denise
Olivero, Alan
Cloughesy, Timothy Francis
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[20] A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHWT GLIOBLASTOMA
Lukas, Rimas
Sachdev, Sean
Kumthekar, Priya
Dixit, Karan
Grimm, Sean
Gondi, Vinai
Sharp, Laura
Lezon, Ray
James, David
Lesniak, Maciej
Stupp, Roger
Wainwright, Derek
NEURO-ONCOLOGY, 2021, 23 : 51 - 52

← 1 2 3 4 5 →